Learn more: bit.ly/46pXpXc Today at #EASD2025, we announced results from our Phase 2 trial investigating the addition of our antibodies to a GLP-1 receptor agonist to assess its impact on quality of weight loss
Results Godex improved insulin sensitivity and significantly decreased fasting plasma glucose, homeostatic model assessment for insulin resistance, steatosis, and gluconeogenesis, with a marked increase in fatty acid oxidation as well as better use of glucose in high-fat diet-fed mice
However, the levels of SOD and GSH-Px (members of the enzymatic antioxidant system) were increased in groups C and D compared with group B
Nasal bioavailability for systemic effects is low, but the nose-to-brain pathway delivers oxytocin directly to central receptors with good efficiency
This is important, since as we age, there is a steady decline in cellular energy